The extent of apoptosis and the expression of Bcl-2 was investigated in tumor samples from 165 women who underwent surgery for primary breast carcinoma between 1989 and 1990 in South-East Sweden. Apoptosis was assessed by a DNA fragmentation assay for flow cytometry. Bcl-2 protein expression was analyzed with immunocytochemistry Bcl-2 immunoreactivity correlated with estrogen receptor (ER) and progesterone receptor (PgR) positivity and was inversely correlated with p53 accumulation. Apoptosis increased with patient age and a high degree of apoptosis was negatively associated with Bcl-2 immunostaining. Apoptosis showed no significant correlation with any of the other variables studied, including prognosis. The group with Bcl-2-positive tumors tended to have a lower risk of distant recurrence than others, but the association of Bcl-2 with recurrence was different in groups divided by ER and PgR status. Whereas Bcl-2 positivity indicated a low recurrence rate among PgR-negative patients, in the PgR-positive group, those with Bcl-2-positive tumors showed a non significantly higher recurrence rate than Bcl-2-negative cases. In the PgR-positive group, Bcl-2-positive tumors also appeared more frequently to be lymph node positive and DNA aneuploid. The results suggest that hormone receptor status is of importance for the prognostic role of Bcl-2. Likewise, patient age merits consideration when apoptosis is studied in human cancer.
LipponenP., AaltomaaS., KosmaV-M, SyrjænenK.Apoptosis in breast cancer as related to histopathological characteristics and prognosis.Eur J Cancer1994; 30A: 2068–73.
2.
SierraA., LloverasB., CastellsaguéX., MorenoL., Garcia-RamirezM., FabraA.Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma.Int J Cancer1995; 60: 54–60.
3.
BodisS., SiziopikouK.P., SchnittS.J., HarrisJ.R., FischerD.E.Extensive apoptosis in ductal carcinoma in situ of the breast.Cancer1996; 77: 1831–5.
4.
MustonenM., RaunioH., PääkköP., SoiniY.The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions.Histopathology1997; 31: 347–54.
5.
SteckK.D., McDonnellT.J., SneigeN., E1-NaggarA.K.Flow cytometric analysis of apoptosis and BCL-2 in primary breast carcinomas: Clinical and biological implications.Cytometry1996; 24: 116–22.
6.
BhargavaV., KellD.L., van de RijnM., WarnkeR.A.Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.Am J Path1994; 145: 535–40.
7.
DoglioniC., Dei TosA.P., LaurinoL., ChiarelliC., BarbareschiM., VialeG.The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.Virchows Arch1994: 424: 47–51.
8.
JoensuuH., PylkkanenL., ToikkanenS.Bcl-2 protein expression and long term survival in breast cancer.Am J Pathol1994; 145: 1191–8.
9.
GorczycaW., MarkiewskiM., KramA., TuziakT., DomagalaW.Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.Virchows Arch1995; 426: 229–33.
10.
GeeJ.M.W., RobertsonJ.F.R., EllisI.O.Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.Int J Cancer1994; 59: 619–28.
11.
HellemansP., van DamP.A., WeylerJ., van OosteromA.T., BuytaertP., Van MarckE.Prognostic value of bcl-2 in invasive breast cancer.Br J Cancer1995; 72: 354–60.
12.
KobayashiS., IwaseH., ItoY.Clinical significance of bcl-2 gene expression in human breast cancer tissues.Breast Cancer Res Treat1997; 42: 173–81.
13.
LeekR.D., KaklamanisL., PezzellaF., GatterK.C., HarrisA.L.bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.Br J Cancer1994; 69: 135–9.
14.
SilvestriniR., VeneroniS., DaidoneM.G.The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.J Natl Cancer Inst1994; 86: 499–504.
15.
LipponenP., PietiläinenT., KosmaV-M, AaltomaaS., EskelinenM., SyrjänenK.Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis.J Pathol1995; 177: 49–55.
16.
StålO., BrisforsA., CarstensenJ., FerraudL., HatschekT., NordenskjöldB.The South-East Sweden Breast Cancer Group. Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening.Int J Cancer1992; 51: 28–33.
17.
CoxD.R.Regression models and life tables (with discussion).J Stat Soc B1972; 34: 187–220.
18.
KaplanE.L., MeierP.Nonparametric estimation from incomplete observations.J Am Stat Assoc1958; 53: 457–81.
19.
DunnS.E., HardmanR.A., KariF.W., BarrettJ.C.Insulinlike growth factor 1 (IGF-1) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs.Cancer Res1997; 57: 2687–93.
20.
ResnicoffM., BurgaudJ.L., RotmanH.L., AbrahamD., BasergaR.Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors.Cancer Res1995; 55: 3739–41.
21.
RubinR., BasergaR.Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity.Lab Invest1995; 73: 311–31.
22.
SellC., BasergaR., RubinR.Insulin-like growth factor I (IGF- I) and the IGF I receptor prevent etoposide-induced apoptosis.Cancer Res1995; 55: 303–6.
23.
Goodman-GruenD., Barrett-ConnorE.Epidemiology of insulin-like growth factor I in elderly men and women. The Rancho Bernardo study.Am J Epidemiol1997; 145: 970–6.
24.
Landin-WilhelmsenK., WilhelmsenL., LappasG.Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin.Clin Endocrinol1994; 41: 351–7.
25.
SilvestriniR., BeniniE., VeneroniS.p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.J Clin Oncol1996; 14: 1604–10.
26.
BauerJ.J., SesterhennI.A., MostofiF.K., McLeodD.G., SrivastavaS., MoulJ.W.Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.J Urol1996; 156: 1511–6.
27.
BubendorfL., SauterG., MochH.Prognostic significance of Bcl-2 in clinically localized prostate cancer.Am J Pathol1996; 148: 1557–65.
28.
WangT.T., PhangJ.M.Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7.Cancer Res1995; 55: 2487–9.
29.
PerryR.R., KangY., GreavesB.R.Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostatis and apoptosis in human breast cancer cells.Br J Cancer1996; 74: 993–4.
